Wow that would be quite left field however I keep coming back to the big pharma buy out experience from guys such as Loveridge and Duthy. These guys have other projects on so I think it makes most sense to get a deal done, maximise their stock options and move on to the next bio. The amount of work that goes into getting a spec bio to market is huge let alone being involved in more than one.
DCF Valuation Model for Invex Therapeutics, page-104
-
- There are more pages in this discussion • 138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
